arBtrage CAPITALIZING MARKETS — checking… Sign in Sign up
Calendar /

LENZ Therapeutics, Inc.

LENZ Health Care Biotechnology: Biological Products (No Diagnostic Substances)
$3.10
▼ -3.9% Today
as of Oct 23, 13:48 ET
Last 30 days -30.98% Sep 14 → Oct 23
$2.97 $3.38 $3.78 $4.18 $4.58 Sep 14 Sep 22 Sep 30 Oct 07 Oct 15 Oct 23
Open
$3.25
High
$3.29
Low
$3.18
Volume
$435,385
Avg Vol
$953,484
Mkt Cap
$114M
P/E (TTM)
—
Beta
—
52w High
$32.92
52w Low
$3.12
Div Yield
—
Shares Out
$31M

Recent Press Releases & News last 60 days · 2 items

Oct 22 · 12:00 PR GlobeNewswire
LENZ Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
Oct 21 · 04:27 Simply Wall St.
LENZ Therapeutics (LENZ) Stock Fair Value Falls After Analysts Cut VIZZ Launch Expectations

LENZ earnings at a glance

LENZ Therapeutics, Inc. (LENZ) is scheduled to report earnings on Wednesday, November 4, 2026 — in 12 days. Analysts expect earnings per share of -$1.01, compared with -$0.59 in the same quarter last year (-71%). The options market is pricing a move of about ±43.5% after the report, a range of roughly $1.75 to $4.45 from today's $3.10. Over its last 6 reports the stock rose the next day 1 time and fell 5, moving ±11.7% on average; after the most recent report on Aug 11, 2026 it moved -3.3%. That means options currently expect more movement than LENZ has typically delivered. LENZ beat the consensus EPS estimate in 4 of its last 6 reported quarters. Implied volatility is currently 269%. The share price of $3.10 sits near its 52-week low.

More Health Care stocks · All stocks · Earnings calendar

Overview

52-week range
$3.12
$33
0% of range
Avg surprise (last 6)
-1.3%
Avg reaction (last 6)
-11.0%
17% positive
Latest IV / EM
269%
EM ±43.5% · $5 · Oct 16

Earnings trends

EPS — actual vs estimate Actual Estimate
$-9.62$-7.31$-5.00$-2.69$-0.38 Actual $-6.50Actual $-7.53Actual $-9.62Actual $-3.53Actual $-0.40Actual $-0.38Actual $-0.53Est $-0.55Actual $-0.53Est $-0.58Actual $-0.59Est $-0.67Actual $-1.16Est $-0.91Actual $-1.32Est $-1.10Actual $-1.02Est $-1.21 MarJunSepMarJunSepMar/2025Jun/2025Sep/20258KMar/2026Jun/2026
Revenue vs Net Income Revenue Net income
$-41M$-28M$-14M$-528,250$13M Sep 24Mar 25Jun 25Sep 25Mar 26Jun 26

Earnings history

DatePeriodActual EPSEstSurpriseYoY %ΔDay reactSource
Tue Aug 11, 2026Jun/2026 $-1.02 $-1.21 +15.7% -128.3% -3.3% earnings
Mon May 11, 2026Mar/2026 $-1.32 $-1.10 -20.0% -149.1% -20.8% earnings
Tue Mar 24, 20268K 2026-03-24 $-1.16 $-0.91 -27.5% — -17.9% earnings
Wed Nov 5, 2025Sep/2025 $-0.59 $-0.67 +11.9% — -23.5% earnings
Wed Jul 30, 2025Jun/2025 $-0.53 $-0.58 +8.6% — -2.9% earnings
Wed May 7, 2025Mar/2025 $-0.53 $-0.55 +3.6% — +2.1% earnings
Mon Sep 30, 2024Sep 2024 $-0.38 — — — — financials
Sun Jun 30, 2024Jun 2024 $-0.40 — — — — financials
Sun Mar 31, 2024Mar 2024 $-3.53 — — — — financials
Sat Sep 30, 2023Sep 2023 $-9.62 — — — — financials
Fri Jun 30, 2023Jun 2023 $-7.53 — — — — financials
Fri Mar 31, 2023Mar 2023 $-6.50 — — — — financials

Upcoming

DateFiscalTimeEPS EstLY EPSYoY %Δ
Wed Nov 4, 2026Sep/2026OTHER -$1.01-$0.59 -71.2%

Financials

Income statement (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue$5M$2M—$12M$5M$0—$0
Cost of revenue$280,000$1M——$0$0——
Gross profit————————
Operating income$-34M$-44M—$-19M$-17M$-17M—$-13M
Net income$-32M$-41M—$-17M$-15M$-15M—$-10M
EPS (diluted)$-1.02$-1.32—$-0.59$-0.53$-0.53—$-0.38

Balance sheet (quarterly)

MetricJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Cash & equivalents$24M$25M$25M$25M$38M$23M$20M$41M
Inventory$4M$3M$3M$949,000——$0—
Total current assets$233M$268M$301M$207M$214M$198M$212M$221M
Total assets$237M$273M$306M$211M$217M$201M$215M$224M
Long-term debt————————
Total liabilities$17M$26M$22M$17M$11M$9M$11M$9M
Total equity$219M$246M$284M$194M$206M$192M$204M$215M

Implied volatility — last 90 days

25%250%475%700%925% Jun 07 — IV 108% · EM ±15.0%Jun 08 — IV 117% · EM ±15.5%Jun 09 — IV 217% · EM ±27.2%Jun 11 — IV 313% · EM ±34.6%Jun 12 — IV 260% · EM ±26.6%Jun 15 — IV 334% · EM ±24.1%Jun 17 — IV 925% · EM ±38.6%Jun 19 — IV 248% · EM ±54.9%Jun 22 — IV 175% · EM ±36.6%Jun 23 — IV 183% · EM ±37.4%Jun 24 — IV 242% · EM ±48.4%Jun 25 — IV 28% · EM ±5.4%Jun 26 — IV 183% · EM ±35.0%Jun 29 — IV 311% · EM ±55.1%Jun 30 — IV 26% · EM ±4.4%Jul 01 — IV 589% · EM ±98.4%Jul 06 — IV 180% · EM ±25.0%Jul 07 — IV 231% · EM ±30.5%Jul 09 — IV 190% · EM ±22.5%Jul 10 — IV 801% · EM ±88.6%Jul 14 — IV 84% · EM ±6.1%Jul 15 — IV 645% · EM ±38.1%Jul 16 — IV 98% · EM ±4.1%Jul 20 — IV 81% · EM ±19.2%Jul 21 — IV 256% · EM ±59.6%Jul 22 — IV 245% · EM ±56.0%Jul 23 — IV 79% · EM ±17.8%Jul 24 — IV 74% · EM ±16.4%Jul 27 — IV 78% · EM ±16.2%Jul 28 — IV 62% · EM ±12.8%Jul 29 — IV 92% · EM ±18.4%Jul 30 — IV 53% · EM ±10.3%Aug 03 — IV 357% · EM ±63.3%Aug 04 — IV 575% · EM ±99.0%Aug 05 — IV 114% · EM ±19.0%Aug 06 — IV 219% · EM ±35.4%Aug 07 — IV 376% · EM ±58.8%Aug 10 — IV 384% · EM ±53.2%Aug 11 — IV 120% · EM ±15.8%Aug 12 — IV 79% · EM ±9.9%Aug 13 — IV 133% · EM ±15.7%Aug 14 — IV 87% · EM ±9.7%Aug 17 — IV 212% · EM ±17.7%Aug 18 — IV 167% · EM ±12.1%Aug 25 — IV 47% · EM ±9.6%Aug 26 — IV 59% · EM ±11.8%Aug 27 — IV 65% · EM ±12.7%Aug 28 — IV 63% · EM ±12.0%Aug 31 — IV 79% · EM ±13.9%Sep 01 — IV 122% · EM ±21.0%Sep 02 — IV 158% · EM ±26.4%Sep 08 — IV 192% · EM ±25.3%Sep 09 — IV 122% · EM ±15.3%Sep 10 — IV 282% · EM ±33.4%Sep 11 — IV 240% · EM ±26.5%Sep 21 — IV 136% · EM ±28.3%Sep 22 — IV 130% · EM ±26.6%Sep 23 — IV 337% · EM ±67.5%Sep 25 — IV 33% · EM ±6.4%Sep 30 — IV 382% · EM ±63.8%Oct 01 — IV 269% · EM ±43.5%

Sector peers

BDTX
Black Diamond Therapeutics, Inc.
$105M $1.89-9.4%
ARMP
Armata Pharmaceuticals, Inc.
$123M $3.61+18.0%
TNYA
Tenaya Therapeutics, Inc.
$127M $0.39+0.5%
ENGN
enGene Therapeutics Inc.
$128M $1.56-4.3%
CRBU
Caribou Biosciences, Inc.
$131M $0.54-0.2%
CGTX
Cognition Therapeutics, Inc.
$89M $0.72-3.9%

LENZ earnings FAQ

When is LENZ's next earnings date?

LENZ Therapeutics, Inc. is expected to report on November 4, 2026.

What is LENZ's expected move for earnings?

Options currently price a move of about ±43.5%, or $1.35 per share either way from $3.10.

How does LENZ stock usually react to earnings?

Across the last 6 reports the average next-day move was ±11.7%, up 1 times and down 5 times.

What EPS are analysts expecting from LENZ Therapeutics, Inc.?

The consensus estimate is -$1.01 per share, versus -$0.59 a year ago.

What is LENZ's implied volatility?

LENZ's at-the-money implied volatility is about 269% based on the latest options snapshot.

View on Nasdaq ↗
🔒 Preview mode. Create a free account to unlock the full earnings calendar, all panels, heatmaps, options flow, and screener.
Sign up free → Sign in